New York’s newly-signed budget contains a key reform that could be nothing short of lifesaving for some cancer patients living in the state. National Cancer Institute-designated cancer centers will become “in-network” for over 5 million New Yorkers who rely on Medicaid, Essential, or Marketplace plans.
The U.S. Food and Drug Administration (FDA) last week approved axicabtagene ciloleucel (axi-cel, Yescarta®) for patients with large B-cell lymphoma (LBCL) who either did not respond to first-line standard chemotherapy or relapsed within 12 months. This is a big step for CAR T because it is now proven that CAR T-therapy can outperform the best therapy we had for certain patients that failed initial therapy.
Just one year after the first CAR T-cell treatment was approved for multiple myeloma, the second is about to hit the market. The FDA approved ciltacabtagene autoleucel (cilta-cel), trade name Carvykti™, last week for patients with relapsed or refractory multiple myeloma who have had at least four previous treatments.
The American Society of Hematology (ASH) annual meeting is the premier scientific forum on blood cancers. More than 5,000 potentially game-changing research abstracts were presented at this year’s meeting. Every year, I come away with a strengthened sense of hope about new treatments on the horizon and renewed pride in The Leukemia & Lymphoma Society’s (LLS) role in supporting so many of them.